Drug Type Small molecule drug |
Synonyms LLME, LeuLeuOMe |
Target- |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC13H26N2O3 |
InChIKeyAJMOLNFDYWTVQW-QWRGUYRKSA-N |
CAS Registry13022-42-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nonalcoholic Steatohepatitis | Phase 2 | US | 19 Nov 2015 | |
Hematologic Neoplasms | Phase 2 | US | 01 Mar 2004 | |
Graft vs Host Disease | Phase 2 | - | - | |
Graft vs Host Disease | Phase 2 | - | - | |
Graft vs Host Disease | Phase 2 | - | - | |
Graft vs Host Disease | Phase 2 | - | - |
Phase 1/2 | 14 | Hematopoietic stem cell transplantation (HSCT)+Mesna+Fludarabine+Cyclophosphamide+Tacrolimus+L-leucyl-L-leucine Methyl Ester (LLME)+Cytarabine | mtuulpytqv(dcilfnhhht) = imyxjipljz thsjbiqtas (vifwncdtsu, njrgqbwgwd - keybaghzrq) View more | - | 10 Dec 2013 | ||
Not Applicable | - | (LLME treated CD34- fraction) | skriemgyss(pnwgdahini) = gznafbwqtx efhnnrrwyf (zvlxhwbham ) View more | - | 01 Feb 2011 | ||
(CD34 selected stem cell product) | skriemgyss(pnwgdahini) = gqbepethfq efhnnrrwyf (zvlxhwbham ) View more |